Arena Pharmaceuticals (Arena Pharmaceuticals) Earnings per Share (Diluted) : $-10.13 (TTM As of Dec. 2021)

View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Earnings per Share (Diluted)?

Arena Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Dec. 2021 was $-2.54. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was $-10.13.

Arena Pharmaceuticals's EPS (Basic) for the three months ended in Dec. 2021 was $-2.54. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2021 was $-10.13.

Arena Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2021 was $-2.54. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2021 was $-10.13.

During the past 3 years, the average EPS without NRIGrowth Rate was -155.20% per year.

During the past 13 years, Arena Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 57.10% per year. The lowest was -155.20% per year. And the median was 8.20% per year.

Arena Pharmaceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for Arena Pharmaceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Earnings per Share (Diluted) Chart

Arena Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-2.77

-0.63

7.69

-7.39

-10.14

Arena Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-2.10	-1.98	-2.40	-3.21	-2.54

Competitive Comparison of Arena Pharmaceuticals's Earnings per Share (Diluted)

For the Biotechnology subindustry, Arena Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arena Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's PE Ratio falls into.

Arena Pharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Arena Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2021 is calculated as

Diluted Earnings Per Share (A: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-616.433	-	0)	/	60.776
	=	-10.14

Arena Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2021 is calculated as

Diluted Earnings Per Share (Q: Dec. 2021 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-155.609	-	0)	/	61.382
	=	-2.54

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.13

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Arena Pharmaceuticals (NAS:ARNA) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Arena Pharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Arena Pharmaceuticals (Arena Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (NAS:ARNA) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Heber Avenue, Suite 204, Park City, UT, USA, 84060

Website

https://www.arenapharm.com

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Executives

Amit Munshi	director, officer: President and CEO	C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Robert Lisicki	officer: EVP, Chief Commercial Officer	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Dallas Jayson Donald Alexander	director	AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Vincent Aurentz	officer: Executive VP and CBO	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Tina Susan Nova	director	C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Christopher Cabell	officer: EVP, Head of R&D, and CMO	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Manmeet Singh Soni	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Kieran Gallahue	director	PO BOX 684369, PARK CITY UT 84068
Katharine Knobil	director	C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Jennifer Jarrett	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Garry Arthur Neil	director	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Oliver Fetzer	director	AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Laurie Stelzer	officer: EVP & Chief Financial Officer	6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Joan Schmidt	officer: EVP, General Counsel & Sec	C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Kevin Robert Lind	officer: Executive VP and CFO	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121